Akeso Biopharma

📍 中山, China🗓 Founded 2012👥 107 employees💰 Last funded Aug 2018
Akeso (HKEX: 09926) is a commercial-stage biopharmaceutical company committed to discovering, developing, manufacturing, and commercializing innovative medicines that address global medical needs. Since our inception, we have established a distinctive and integrated R&D innovation system with the comprehensive end-to-end drug development platform (ACE Platform) and bi-specific antibody drug development technology (Tetrabody) as the fundamental components, a GMP-compliant manufacturing system and a commercialization system with an advanced operation mode.   Akeso is actively developing a diverse pipeline of over 50 innovative assets in cancer, autoimmune disease, inflammation, metabolic disease, and other therapeutic fields. Among these, 19 assets have entered the clinical stage, with 3 innovative drugs already approved, and 13 pivotal/phase III trials ongoing. Utilizing its proprietary Tetrabody technology, Akeso has successfully developed the first-in-class PD-1/CTLA-4 bispecific antibody drug for the market. Additionally, the company has five other innovative bispecific antibody drugs in the clinical stage, including ivonescimab (PD-1/VEGF), PD-1/LAG-3, TIGIT/TGF-Beta, PD-1/CD73, and claudin18.2/CD47 bispecific antibodies.
1
Total investors
0
Early stage
0
Mid stage
1
Late stage
2012
Founded
Investor geography1 country
China
1
Frequently asked questions
Who invested in Akeso Biopharma?
Akeso Biopharma has 1 investors on record on gritt.io and 1 late-stage investors.
When did Akeso Biopharma last raise funding?
The most recent investment in Akeso Biopharma recorded on gritt.io was in August 2018.
When was Akeso Biopharma founded?
Akeso Biopharma was founded in 2012.
What industry is Akeso Biopharma in?
Akeso Biopharma operates in Pharmaceutical Manufacturing. Find similar Pharmaceutical Manufacturing investors on gritt.io.
Where is Akeso Biopharma based?
Akeso Biopharma is headquartered in 中山, China.